BY CHRISTIAN BUNDGAARD
-
Less parallel trade with ALK’s tablet vaccines boosts earnings in Q2
ALK has actually not been as hard struck by identical sell the business’s allergic reaction vaccinations in tablet kind as in previous years, which has actually added to a fa…
-
Lundbeck CEO attributes sales boost to US TV commercials
Numerous of Lundbeck’s crucial tactical items offered greater than both the pharmaceutical business and experts had actually anticipated last quarter, causing a higher modifi…
-
Lundbeck upgrades guidance after strong second quarter
Lundbeck has actually seen double-digit development prices in the 2nd quarter, providing reason for a brighter overview on the business’s monetary efficiency for the complete…
-
Coloplast performs as expected, reports 8% organic growth in Q3
The Advanced Injury Treatment department was a specifically solid development motorist.
-
Eli Lilly board member steps down
After 10 years on the board, Marschall S. Runge is retiring.
-
Novo Nordisk cannot feel the competition: “Everything we make, we sell”
Novo Nordisk has scaled up the manufacturing of semaglutide for Wegovy considerably, and that is mirrored within the prescription figures.
-
Pharmacosmos acquires US biotech company G1 Therapeutics
G1 Therapies investors will certainly get $7.15 per share in a deal valued at $405 million.
-
Novo Nordisk has lost DKK 653 billion in value: Increasing competition threatens share price
Over the summer time, Swiss firm Roche introduced promising information with an weight problems pill.
-
WSA writes off DKK billions: Takes a big hit in the income statement
A brand new depreciation interval at WSA will end in a complete extra expense on the revenue assertion of over DKK 8 billion already this 12 months.
-
Danish obesity startup to raise up to DKK 370 million in first major investment round
Fairness is gone at Antag Therapeutics, which is why the corporate is now working to boost DKK hundreds of thousands to get its lead candidate into the clinic.
